BioNTech logo” title=”BioNTech logo” class=”companylogo”/>BioNTech ((NASDAQ:(BNTX))) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.
(BNTX) has been the topic of several other research reports. Berenberg Bank set a $126.00 price target on shares of BioNTech and gave the stock a “buy” rating in a research note on Monday, January 11th. Bank of America downgraded shares of BioNTech from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $123.00 to $126.00 in a research note on Monday, November 30th. SVB Leerink lifted their price target on shares of BioNTech from $97.00 to $106.00 and gave the stock a “market perform” rating in a research note on Thursday, February 4th. Finally, Canaccord Genuity raised their price objective on shares of BioNTech from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, December 14th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $99.56.
BioNTech stock traded up $8.51 during midday trading on Tuesday, hitting $104.42. 84,350 shares of the stock were exchanged, compared to its average volume of 1,902,003. BioNTech has a 1 year low of $37.00 and a 1 year high of $131.00. The firm has a market cap of $25.14 billion, a P/E ratio of -52.21 and a beta of -1.74. The company has a 50 day moving average price of $107.12 and a two-hundred day moving average price of $98.57.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Trexquant Investment LP boosted its holdings in shares of BioNTech by 38.0% in the 4th quarter. Trexquant Investment LP now owns 25,198 shares of the company’s stock valued at $2,054,000 after buying an additional 6,933 shares during the period. Quinn Opportunity Partners LLC acquired a new position in BioNTech during the 4th quarter valued at about $774,000. Vestcor Inc acquired a new position in BioNTech during the 3rd quarter valued at about $2,700,000. Sei Investments Co. raised its position in shares of BioNTech by 28.4% during the 3rd quarter. Sei Investments Co. now owns 52,814 shares of the company’s stock worth $3,656,000 after buying an additional 11,695 shares in the last quarter. Finally, Morgan Stanley raised its position in shares of BioNTech by 328.1% during the 3rd quarter. Morgan Stanley now owns 99,336 shares of the company’s stock worth $6,877,000 after buying an additional 76,131 shares in the last quarter. 10.75% of the stock is owned by institutional investors and hedge funds.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer.
Featured Article: SEC Filing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]